Personal wealth on the rocket, but musk risks being knocked down by the new crown

category:Finance
 Personal wealth on the rocket, but musk risks being knocked down by the new crown


Elon Musk, CEO of Tesla. Information from Xinhua News Agency

In the latest twitter interaction released on November 19, musk responded to netizens that he had completely recovered from his cold. Last week, musk said he had mild cold symptoms and speculated that he might have contracted a new crown. He tried several new coronavirus tests, and the results were two negative and two positive, which made musk confused and argued with netizens on twitter.

Meanwhile, according to real-time statistics released by Johns Hopkins University in the United States, as of the evening of the 18th EDT, there were more than 11.5 million new crown confirmed cases and more than 250000 deaths in the United States.

According to the data released by the Centers for Disease Control and prevention on the 18th, 164382 new cases were reported in the United States on the 17th. More than 100000 new cases were confirmed in a single day for the 10th consecutive day.

With the coming of winter, the infection data in the United States is surging. However, the reliability and accessibility of detection kits are still the obstacles for epidemic prevention and control.

Musk is likely to be infected

After SpaceX wins the formal commercial contract from NASA, Tesla, the worlds largest car manufacturer by market value, will also be included in the S & P Dow Jones index and become one of the most influential constituent stocks in the index. Its weight will be equal to that of Berkshire Hathaway, Johnson & Johnson and Procter & gamble.

So far this year, Teslas share price has soared more than four times, and its market value has risen to more than $400 billion. Musk owns about 20% of Teslas shares. That added $15 billion to Musks wealth in a week, overtaking Facebook founder and CEO Mark Zuckerberg to become the third richest person in the world.

On Nov. Among the four test results, two times were negative and two times were positive. The same equipment, reagent and personnel were used. He also specifically named the detection reagent and equipment from BD, a US medical equipment giant, for rapid antigen detection.

Musk also said he was tested for PCR nucleic acids. Although he did not disclose the results of the nucleic acid test, he interacted with Michael Mina, a public health expert at Harvard University, who asked musk: how much CT value of nucleic acid test can prove to be a new crown positive? This suggests that Musks nucleic acid test results are likely to be positive. However, musk has not publicly confirmed his infection with the new crown.

On the 15th, SpaceXs Dragon spacecraft carried four astronauts to the international space station, but musk was absent from the launch site.

According to the FDA guidelines, people who are positive for the test should be self isolated and seek additional care from their health care providers. The FDA also said those who had negative tests but had symptoms similar to new crowns should also actively seek follow-up from health care providers.

Although antigen and antibody detection is usually regarded as the gold standard for in vitro diagnosis, experts suggest that in the early stage of infection, the sensitivity of antigen antibody detection reagent is insufficient, which makes this detection method unable to play a major role in diagnosis, and should be used as a supplement when nucleic acid is negative.

It has been reported that the false negative rate of veritor, a new rapid detection reagent produced by BD company, is 16%. Moreover, due to the influence of sampling and other factors, antigen detection products can easily lead to false positive results, which can mistakenly identify healthy people as infected persons.

The advantage of antigen detection is that the results can be obtained quickly, but the accuracy is poor. Unlike PCR nucleic acid detection from viral molecular detection method, antigen detection is an immunological detection method, through blood sampling to determine the virus antigen.

As the epidemic is spreading, it is necessary to use large-scale antigen and antibody detection reagents as a screening tool for asymptomatic patients. However, under the background of FDAs emergency use authorization, the accuracy of antigen detection has been questioned.

Demand for new crown detection is in short supply

However, the rapid development of the epidemic situation in the United States and Europe since the autumn calls for the enhancement of detection capabilities.

New York once again took strict measures to control the epidemic. The picture shows the Times Square in New York recently.

At the end of September this year, BD announced that veritor, a new rapid detection reagent with results within 15 minutes, had obtained the EU CE certification and was launched in Europe at the end of October.

BD said the new test method can be carried out on a small portable instrument, which is critical to the turnaround time of the new crown diagnosis because it can provide real-time results and allow patients to make judgments while they are still in the field.

BD is not the only company to develop a rapid antigen test system for the new coronavirus.

Novel coronavirus PCR nucleic acid detection is more accurate than antigen detection at the end of last month, Dr. Roche CEO SeverinSchwan said, and has always been the main detection tool since its popularity. However, due to the limitation of production capacity, the monthly production capacity will not exceed 1000 million.

With the rapid increase in the number of new coronavirus cases worldwide, European countries, including Germany and France, have introduced new restrictive measures. Epidemic prevention and control agencies are increasingly turning to antigen detection, including the use of antigen detection reagents from Roche and its Korean partner sdbiosensor, as well as antigen detection reagents from competitors such as Abbott Laboratories and Siemens Medical to cope with the shortage of supply.

Roche is also developing an antigen test based on saliva. Roche has also announced a 15 minute antigen test in early September and obtained CE certification. Qiagen, the German manufacturer of diagnostic tests, also announced last month that it plans to launch a 15 minute antigen test.

At the same time, the U.S. FDA on November 18, for the first time, approved a new crown detection reagent that can be carried out completely at home. Results can be provided within 30 minutes by nasal swab test, which is applicable to suspected patients with new crown aged 14 and above.

Developed by lucira health, a California based biotechnology company, the reagent can rotate the swab in a vial and display the results on the devices display screen within 30 minutes.

The FDA did not disclose the price of the test, but the companys website shows that the cost of the test is expected to be less than $50 (about 330 yuan).

Experts say that with the arrival of the autumn and winter flu season in the northern hemisphere, superimposed infections will make it more difficult to detect new crowns. Qiagen announced on November 16 a new detection reagent that can help healthcare professionals quickly identify and differentiate common seasonal respiratory infections and new crown patients.

As the northern hemisphere is in the flu season, this new PCR nucleic acid detection method can detect and distinguish influenza A and B, respiratory syncytial virus (RSV) and new coronal infection within 80 minutes, Qiagen told the first financial reporter

Currently, Qiagen has submitted an emergency use authorization application to FDA.

Qiagen reported last month that sales in the third quarter rose 26% more than expected due to strong demand for the new crown test. At the beginning of this month, BD also released its third quarter earnings of US $2.79 per share, with both profits and revenues exceeding expectations; sales of new crown related products (such as test kits) soared, driving growth in performance. Roches sales of diagnostic products rose 18% in the third quarter of this year to 3.6 billion Swiss francs (about 26 billion yuan). In response to the surge of new crown infections in autumn and winter and the risk of virus transmission brought about by the coming holiday season in the United States, the United States has increased its new prevention and control measures. Industry analysis predicts that by 2021, Xinguan detection reagent will still maintain a high demand state of normalization. Source of this article: Guo Chenqi, editor in charge of first finance and Economics_ NBJ9931

Qiagen reported last month that sales in the third quarter rose 26% more than expected due to strong demand for the new crown test.

At the beginning of this month, BD also released its third quarter earnings of US $2.79 per share, with both profits and revenues exceeding expectations; sales of new crown related products (such as test kits) soared, driving growth in performance.

Roches sales of diagnostic products rose 18% in the third quarter of this year to 3.6 billion Swiss francs (about 26 billion yuan).